198 related articles for article (PubMed ID: 36980879)
1. NAD(P)H Quinone Oxidoreductase-1 Expression Promotes Self-Renewal and Therapeutic Resistance in Non-Small Cell Lung Cancer.
Madajewski B; Boatman MA; Martinez I; Carter JH; Bey EA
Genes (Basel); 2023 Feb; 14(3):. PubMed ID: 36980879
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Small Molecules Simultaneously Targeting NAD(P)H:Quinone Oxidoreductase 1 and Nicotinamide Phosphoribosyltransferase: Treatment of Drug-Resistant Non-small-Cell Lung Cancer.
Zhang K; Wang K; Zhang X; Qian Z; Zhang W; Zheng X; Wang J; Jiang Y; Zhang W; Lu Z; Hao H; Jiang S
J Med Chem; 2022 Jun; 65(11):7746-7769. PubMed ID: 35640078
[TBL] [Abstract][Full Text] [Related]
3. Fighting drug-resistant lung cancer by induction of NAD(P)H:quinone oxidoreductase 1 (NQO1)-mediated ferroptosis.
Yu J; Zhong B; Zhao L; Hou Y; Ai N; Lu JJ; Ge W; Chen X
Drug Resist Updat; 2023 Sep; 70():100977. PubMed ID: 37321064
[TBL] [Abstract][Full Text] [Related]
4. Discovery of Nonquinone Substrates for NAD(P)H: Quinone Oxidoreductase 1 (NQO1) as Effective Intracellular ROS Generators for the Treatment of Drug-Resistant Non-Small-Cell Lung Cancer.
Wu X; Li X; Li Z; Yu Y; You Q; Zhang X
J Med Chem; 2018 Dec; 61(24):11280-11297. PubMed ID: 30508483
[TBL] [Abstract][Full Text] [Related]
5. C609T polymorphism of NAD(P)H quinone oxidoreductase 1 as a predictive biomarker for response to amrubicin.
Takakuwa O; Oguri T; Ozasa H; Uemura T; Kunii E; Kasai D; Miyazaki M; Maeno K; Sato S
J Thorac Oncol; 2011 Nov; 6(11):1826-32. PubMed ID: 21964527
[TBL] [Abstract][Full Text] [Related]
6. Depleting Tumor-NQO1 Potentiates Anoikis and Inhibits Growth of NSCLC.
Madajewski B; Boatman MA; Chakrabarti G; Boothman DA; Bey EA
Mol Cancer Res; 2016 Jan; 14(1):14-25. PubMed ID: 26553038
[TBL] [Abstract][Full Text] [Related]
7. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
Bey EA; Bentle MS; Reinicke KE; Dong Y; Yang CR; Girard L; Minna JD; Bornmann WG; Gao J; Boothman DA
Proc Natl Acad Sci U S A; 2007 Jul; 104(28):11832-7. PubMed ID: 17609380
[TBL] [Abstract][Full Text] [Related]
8. Dual-negative expression of Nrf2 and NQO1 predicts superior outcomes in patients with non-small cell lung cancer.
Tong YH; Zhang B; Yan YY; Fan Y; Yu JW; Kong SS; Zhang D; Fang L; Su D; Lin NM
Oncotarget; 2017 Jul; 8(28):45750-45758. PubMed ID: 28501854
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone.
Torrente L; Prieto-Farigua N; Falzone A; Elkins CM; Boothman DA; Haura EB; DeNicola GM
Redox Biol; 2020 Feb; 30():101440. PubMed ID: 32007910
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors.
Siegel D; Franklin WA; Ross D
Clin Cancer Res; 1998 Sep; 4(9):2065-70. PubMed ID: 9748120
[TBL] [Abstract][Full Text] [Related]
11. Development of a new isogenic cell-xenograft system for evaluation of NAD(P)H:quinone oxidoreductase-directed antitumor quinones: evaluation of the activity of RH1.
Dehn DL; Winski SL; Ross D
Clin Cancer Res; 2004 May; 10(9):3147-55. PubMed ID: 15131056
[TBL] [Abstract][Full Text] [Related]
12. A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent.
Winski SL; Hargreaves RH; Butler J; Ross D
Clin Cancer Res; 1998 Dec; 4(12):3083-8. PubMed ID: 9865924
[TBL] [Abstract][Full Text] [Related]
13. NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones.
Siegel D; Yan C; Ross D
Biochem Pharmacol; 2012 Apr; 83(8):1033-40. PubMed ID: 22209713
[TBL] [Abstract][Full Text] [Related]
14. NAD(P)H:quinone oxidoreductase 1 (NQO1) localizes to the mitotic spindle in human cells.
Siegel D; Kepa JK; Ross D
PLoS One; 2012; 7(9):e44861. PubMed ID: 22984577
[TBL] [Abstract][Full Text] [Related]
15. Enhanced glycometabolism as a mechanism of NQO1 potentiated growth of NSCLC revealed by metabolomic profiling.
Cheng X; Liu F; Liu H; Wang G; Hao H
Biochem Biophys Res Commun; 2018 Jan; 496(1):31-36. PubMed ID: 29291405
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase).
Traver RD; Siegel D; Beall HD; Phillips RM; Gibson NW; Franklin WA; Ross D
Br J Cancer; 1997; 75(1):69-75. PubMed ID: 9000600
[TBL] [Abstract][Full Text] [Related]
17. NAD(P)H-dependent quinone oxidoreductase 1 (NQO1) and cytochrome P450 oxidoreductase (CYP450OR) differentially regulate menadione-mediated alterations in redox status, survival and metabolism in pancreatic β-cells.
Gray JP; Karandrea S; Burgos DZ; Jaiswal AA; Heart EA
Toxicol Lett; 2016 Nov; 262():1-11. PubMed ID: 27558805
[TBL] [Abstract][Full Text] [Related]
18. Antioxidative enzyme NAD(P)H quinone oxidoreductase 1 (NQO1) modulates the differentiation of Th17 cells by regulating ROS levels.
Nishida-Tamehiro K; Kimura A; Tsubata T; Takahashi S; Suzuki H
PLoS One; 2022; 17(7):e0272090. PubMed ID: 35905076
[TBL] [Abstract][Full Text] [Related]
19. NQO1-dependent, Tumor-selective Radiosensitization of Non-small Cell Lung Cancers.
Motea EA; Huang X; Singh N; Kilgore JA; Williams NS; Xie XJ; Gerber DE; Beg MS; Bey EA; Boothman DA
Clin Cancer Res; 2019 Apr; 25(8):2601-2609. PubMed ID: 30617135
[TBL] [Abstract][Full Text] [Related]
20. An NQO1-initiated and p53-independent apoptotic pathway determines the anti-tumor effect of tanshinone IIA against non-small cell lung cancer.
Liu F; Yu G; Wang G; Liu H; Wu X; Wang Q; Liu M; Liao K; Wu M; Cheng X; Hao H
PLoS One; 2012; 7(7):e42138. PubMed ID: 22848731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
